fenofibrate has been researched along with Acute Edematous Pancreatitis in 9 studies
Pharmavit: a polyvitamin product, comprising vitamins A, D2, B1, B2, B6, C, E, nicotinamide, & calcium pantothene; may be a promising agent for application to human populations exposed to carcinogenic and genetic hazards of ionizing radiation; RN from CHEMLINE
Excerpt | Relevance | Reference |
---|---|---|
"We report a case of rhabdomyolysis and ARF due to fenofibrate monotherapy in a 68-year-old female with post-pancreatitis diabetes mellitus and review reported cases of rhabdomyolysis correlated with fibrates monotherapy." | 7.96 | Fenofibrate monotherapy-induced rhabdomyolysis in a patient with post-pancreatitis diabetes mellitus: A rare case report and a review of the literature. ( Cheng, Q; Li, D; Zhou, J, 2020) |
"Fenofibrate was used safely and successfully during pregnancy in this case of hypertriglyceridemia-associated pancreatitis refractory to conservative measures." | 7.77 | Hyperlipidemia-associated pancreatitis in pregnancy managed with fenofibrate. ( Lorenz, RP; Smith, JM; Whitten, AE, 2011) |
"Bexarotene is a synthetic retinoid from the subclass of retinoids called rexinoids which selectively activate retinoid X receptors." | 5.39 | U.K. consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T-cell lymphoma. ( Azurdia, R; Cowan, R; Eagle, M; Gallop-Evans, E; Graham-Brown, R; Illidge, T; Morris, S; Parry, E; Scarisbrick, JJ; Soran, H; Wachsmuth, R; Wain, EM; Whittaker, S; Wierzbicki, AS, 2013) |
"We report a case of rhabdomyolysis and ARF due to fenofibrate monotherapy in a 68-year-old female with post-pancreatitis diabetes mellitus and review reported cases of rhabdomyolysis correlated with fibrates monotherapy." | 3.96 | Fenofibrate monotherapy-induced rhabdomyolysis in a patient with post-pancreatitis diabetes mellitus: A rare case report and a review of the literature. ( Cheng, Q; Li, D; Zhou, J, 2020) |
"Fenofibrate was used safely and successfully during pregnancy in this case of hypertriglyceridemia-associated pancreatitis refractory to conservative measures." | 3.77 | Hyperlipidemia-associated pancreatitis in pregnancy managed with fenofibrate. ( Lorenz, RP; Smith, JM; Whitten, AE, 2011) |
"Hypertriglyceridemia is an important and under-diagnosed etiology of acute non-biliary pancreatitis." | 1.39 | An acute edematous pancreatitis case developed on the basis of hypertriglyceridemia. ( Aslan, T; Aykas, F; Erden, A; Karagoz, H; Karahan, S; Karaman, A; Mutlu, H; Uslu, E, 2013) |
"Bexarotene is a synthetic retinoid from the subclass of retinoids called rexinoids which selectively activate retinoid X receptors." | 1.39 | U.K. consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T-cell lymphoma. ( Azurdia, R; Cowan, R; Eagle, M; Gallop-Evans, E; Graham-Brown, R; Illidge, T; Morris, S; Parry, E; Scarisbrick, JJ; Soran, H; Wachsmuth, R; Wain, EM; Whittaker, S; Wierzbicki, AS, 2013) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (22.22) | 29.6817 |
2010's | 5 (55.56) | 24.3611 |
2020's | 2 (22.22) | 2.80 |
Authors | Studies |
---|---|
Imai, M | 1 |
Yamamoto, H | 1 |
Hashimoto, T | 1 |
Koyama, H | 1 |
Kihara, S | 1 |
Zhou, J | 1 |
Li, D | 1 |
Cheng, Q | 1 |
Cornejo-Uixeda, S | 1 |
Escoin-Pérez, C | 1 |
Hernandez-Lorente, E | 1 |
Aslan, T | 1 |
Erden, A | 1 |
Karagoz, H | 1 |
Karahan, S | 1 |
Aykas, F | 1 |
Uslu, E | 1 |
Mutlu, H | 1 |
Karaman, A | 1 |
Béliard-Lasserre, S | 1 |
Whitten, AE | 1 |
Lorenz, RP | 1 |
Smith, JM | 1 |
Scarisbrick, JJ | 1 |
Morris, S | 1 |
Azurdia, R | 1 |
Illidge, T | 1 |
Parry, E | 1 |
Graham-Brown, R | 1 |
Cowan, R | 1 |
Gallop-Evans, E | 1 |
Wachsmuth, R | 1 |
Eagle, M | 1 |
Wierzbicki, AS | 2 |
Soran, H | 1 |
Whittaker, S | 1 |
Wain, EM | 1 |
Sato, I | 1 |
Hyakuta, M | 1 |
Hayashi, F | 1 |
Mukai, M | 1 |
Kondo, S | 1 |
Maeda, E | 1 |
Kumagai, S | 1 |
Mikhailidis, DP | 1 |
Wray, R | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
FEnofibRate as a Metabolic INtervention for Coronavirus Disease 2019[NCT04517396] | Phase 2 | 701 participants (Actual) | Interventional | 2020-08-18 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Death from any cause during the observation period (NCT04517396)
Timeframe: Up to 30 days
Intervention | Participants (Count of Participants) |
---|---|
Fenofibrate + Usual Care | 19 |
Placebo + Usual Care | 22 |
The exploratory global rank score, or global severity score, is a nonparametric, hierarchically ranked outcome. The global rank score was generated by ranking all 701 participants on a scale of 1 to 701, from worst to best clinical outcomes. Participants were ranked by (1) time to death; (2) the number of days supported by invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); (3) The inspired concentration of oxygen/percent oxygen saturation (FiO2/SpO2) ratio area under the curve; (4) The number of days out of the hospital during the 30 day-period following randomization. (NCT04517396)
Timeframe: Up to 30 days
Intervention | score on a scale (Median) |
---|---|
Fenofibrate + Usual Care | 5.03 |
Placebo + Usual Care | 5.03 |
Number of days that participants were alive and out of the hospital during the 30 days following randomization (NCT04517396)
Timeframe: Up to 30 days
Intervention | days (Median) |
---|---|
Fenofibrate + Usual Care | 30 |
Placebo + Usual Care | 30 |
Number of days participants were alive, out of the intensive care unit, free of mechanical ventilation/extracorporeal membrane oxygenation, or maximal available respiratory support during the 30 days that followed randomization (NCT04517396)
Timeframe: Up to 30 days
Intervention | days (Mean) |
---|---|
Fenofibrate + Usual Care | 28.8 |
Placebo + Usual Care | 28.3 |
The primary endpoint of the trial is a global rank score that ranks patient outcomes according to 5 factors. The global rank score, or global severity score, is a nonparametric, hierarchically ranked outcome. The global rank score was generated by ranking all 701 participants on a scale of 1 to 701, from worst to best clinical outcomes. Participants were ranked by (1) time to death; (2) the number of days supported by invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); (3) The inspired concentration of oxygen/percent oxygen saturation (FiO2/SpO2) ratio area under the curve; (4) For participants enrolled as outpatients who are subsequently hospitalized, the number of days out of the hospital during the 30 day-period following randomization; (5) For participants enrolled as outpatients who don't get hospitalized during the 30-day observation period, the modified Borg dyspnea scale (NCT04517396)
Timeframe: 30 days
Intervention | Ranked Severity Score (Median) |
---|---|
Fenofibrate + Usual Care | 5.32 |
Placebo + Usual Care | 5.33 |
The secondary global rank score, or global severity score, is a nonparametric, hierarchically ranked outcome. The global rank score was generated by ranking all 701 participants on a scale of 1 to 701, from worst to best clinical outcomes. Participants were ranked by (1) time to death; (2) the number of days supported by invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); (3) The inspired concentration of oxygen/percent oxygen saturation (FiO2/SpO2) ratio area under the curve; (4) For participants enrolled as outpatients who are subsequently hospitalized, the number of days out of the hospital during the 30 day-period following randomization; (5) For participants enrolled as outpatients who don't get hospitalized during the 30-day observation period, a COVID-19 symptom scale rating fever, cough, dyspnea, muscle aches, sore throat, loss of smell or taste, headache, diarrhea, fatigue, nausea/vomiting, chest pain (each are rated from 0-10 then summed). (NCT04517396)
Timeframe: Up to 30 days
Intervention | score on a scale (Median) |
---|---|
Fenofibrate + Usual Care | 5.05 |
Placebo + Usual Care | 5.05 |
A seven-category ordinal scale consisting of the following categories: 1, not hospitalized with resumption of normal activities; 2, not hospitalized, but unable to resume normal activities; 3, hospitalized, not requiring supplemental oxygen; 4, hospitalized, requiring supplemental oxygen; 5, hospitalized, requiring nasal high-flow oxygen therapy, noninvasive mechanical ventilation, or both; 6, hospitalized, requiring extracorporeal membrane oxygenation (ECMO), invasive mechanical ventilation, or both; and 7, death. (NCT04517396)
Timeframe: At 15 days
Intervention | score on a scale (Median) |
---|---|
Fenofibrate + Usual Care | 1 |
Placebo + Usual Care | 1 |
1 review available for fenofibrate and Acute Edematous Pancreatitis
Article | Year |
---|---|
Drug treatment of combined hyperlipidemia.
Topics: Acute Disease; Clofibric Acid; Diabetes Mellitus, Type 2; Female; Fenofibrate; Humans; Hydroxymethyl | 2001 |
8 other studies available for fenofibrate and Acute Edematous Pancreatitis
Article | Year |
---|---|
Acquired marked hypertriglyceridemia with anti-GPIHBP1 antibodies.
Topics: Adolescent; Anti-Inflammatory Agents; Autoantibodies; Diet, Fat-Restricted; Female; Fenofibrate; Hum | 2020 |
Fenofibrate monotherapy-induced rhabdomyolysis in a patient with post-pancreatitis diabetes mellitus: A rare case report and a review of the literature.
Topics: Aged; Diabetes Mellitus; Female; Fenofibrate; Humans; Hypertriglyceridemia; Pancreatitis; Rhabdomyol | 2020 |
Capecitabine-induced pancreatitits.
Topics: Abdomen, Acute; Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Capecitabine; Combined Modali | 2018 |
An acute edematous pancreatitis case developed on the basis of hypertriglyceridemia.
Topics: Adult; Anticoagulants; Diabetes Mellitus, Type 2; Enzyme Activation; Female; Fenofibrate; Heparin; H | 2013 |
[Fibrates: their prescription must be restricted].
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Prescriptions; Fenofibrate; Fibric Acids; F | 2015 |
Hyperlipidemia-associated pancreatitis in pregnancy managed with fenofibrate.
Topics: Adult; Blood Glucose; Female; Fenofibrate; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Infan | 2011 |
U.K. consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T-cell lymphoma.
Topics: Adult; Amylases; Anticarcinogenic Agents; Bexarotene; Blood Cell Count; Blood Glucose; Cholesterol, | 2013 |
[Usefulness of examination of the cholesterol versus triglyceride ratio for lipoprotein fractions in a patient with marked hyper-triglyceridemia].
Topics: Acute Disease; Adult; Biomarkers; Cholesterol; Fenofibrate; Humans; Hypertriglyceridemia; Lipoprotei | 2002 |